China, with its reformed priority review and approval processes, is supporting biotech revolution in the country and thereby allowing domestic drug developers to compete with well-established multinational counterparts.
Against this backdrop, China’s rise will result in more innovation and have the highest positive impact on the pharmaceutical industry in 2019, says data and analytics company GlobalData.
According to GlobalData, the number of cancer patients is on the rise in China and nearly 10,000 diagnosed melanoma cases were recorded in 2017. As a result, the Chinese government is eager to provide better and more affordable cancer care to its citizens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze